Praxis Precision Medicines (PRAX) Accounts Payables (2019 - 2026)

Praxis Precision Medicines' Accounts Payables history runs 8 years deep, the most recent figure standing at $31.2 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 36.01% year-over-year to $31.2 million; the TTM figure through Mar 2026 stood at $31.2 million (up 36.01% YoY), while the FY2025 annual figure was $24.6 million, up 96.58% from the prior year.
• Accounts Payables for Q1 2026 stood at $31.2 million, up from $24.6 million in the prior quarter.
• The five-year high for Accounts Payables was $31.2 million in Q1 2026, with the low at $5.8 million in Q4 2023.
• The 5-year median for Accounts Payables is $13.3 million (2022), against an average of $16.0 million.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables tumbled 60.37% in 2023, then jumped 251.82% in 2025.
• Praxis Precision Medicines' Accounts Payables stood at $14.7 million in 2022, then sank by 60.37% to $5.8 million in 2023, then surged by 115.44% to $12.5 million in 2024, then jumped by 96.58% to $24.6 million in 2025, then grew by 26.51% to $31.2 million in 2026.
• Business Quant data shows PRAX's Accounts Payables at $31.2 million in Q1 2026, $24.6 million in Q4 2025, and $30.8 million in Q3 2025.